CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.

ABSTRACT:

Background

CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications.

Results

To better understand the mode of action of anti-CD40 mAbs, we have determined the x-ray crystal

SUBMITTER: Argiriadi MA 

PROVIDER: S-EPMC6683420 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature